CompletedPhase 2NCT02247544

Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma

Studying Well-differentiated liposarcoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Italian Sarcoma Group
Principal Investigator: Paolo G. Casali, MD
IRCCS Fondazione Istituto Nazionale per la cura dei tumori di Milano
Intervention: Trabectedin(drug)
Enrollment: 105 enrolled
Eligibility: 18 years · All sexes
Timeline: 2014 – 2019

Study locations (21)

Istituto Tumori Giovanni Paolo II, Bari, BA, Italy
Azienda Ospedaliera Giovanni Paolo XXIII, Bergamo, BG, Italy
Azienda Ospedaliera S. Orsola-Malpighi, Bologna, BO, Italy
A.O. Spedali Civili, Brescia, BS, Italy
Ospedale Oncologico A. Businco, Cagliari, CA, Italy
Azienda Ospedaliera S Croce e Carle, Cuneo, CN, Italy
Azienda Ospedaliera Sant'Anna, Como, CO, Italy
IRST IRCCS Meldola, Meldola, FC, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy
Istituto Europeo di Oncologia, Milan, MI, Italy
Istituto Clinico Humanitas, Rozzano, MI, Italy
Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo, PA, Italy
Centro di Riferimento Oncologico di Aviano, Aviano, PD, Italy
Istituto Oncologico Veneto, Padua, PD, Italy
Azienda Ospedaliera Universitaria Santa Chiara, Pisa, PI, Italy
+6 more locations on ClinicalTrials.gov

Collaborators

Istituto Di Ricerche Farmacologiche Mario Negri

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02247544 on ClinicalTrials.gov

Other trials for Well-differentiated liposarcoma

Additional recruiting or active studies for the same condition.

See all trials for Well-differentiated liposarcoma →

← Back to all trials